Johnson & Johnson CEO Signals Clear Strategic Shift Away from GLP-1 Weight-Loss Drugs

Johnson & JohnsonCEO Joaquín Duato explicitly announced at a public event in Washington on June 16 that the company would not enter the GLP-1 weight-loss drug market, choosing instead to allocate resources to oncology and neurological disorders, where it holds a first-mover advantage—a decision that surpassed prior market expectations.

Key Data:
1. Goldman SachsThe global market for weight-loss drugs is projected to reach approximately $95 billion in 2030, with I-MAK estimating that in the same yearEli LillyandNovo NordiskCumulative Revenue of Five Core GLP-1 Drugs to Reach Approximately $470 Billion
2. Johnson & Johnson reported first-quarter 2026 revenue of approximately $24 billion, a year-on-year increase of nearly 10%, with its multiple myeloma business generating single-quarter revenue of around $4 billion; the company has set a goal to become the world’s largest oncology pharmaceutical company by 2030, with a target of $50 billion in total oncology sales.
3. Johnson & Johnson’s current stock price is approximately $239, having risen about 15% year-to-date, approaching its 52-week high of $251.71. Its market capitalization stands at nearly $576 billion, with a price-to-earnings ratio of approximately 28 and a dividend yield of 2.2%;Morgan StanleyHas raised its target price to $283
4. Johnson & Johnson has acquired Harbinger Therapeutics for $3.05 billion and Firefly Bioworks for $1 billion, thereby strengthening its oncology pipeline.

The core logic of this strategic choice is that the GLP-1 sector is already dominated by Eli Lilly and Novo Nordisk, which will subsequently lead to price wars, making it difficult for Johnson & Johnson, as a late entrant, to gain a competitive advantage. By focusing on its proprietary strengths in the oncology sector, the company can achieve more stable growth with a stronger moat, while simultaneously hedging against the risk of declining revenue from its immunology drug Stelara due to the impact of generic drugs.JPMorgan ChaseIt is estimated that by the early 2030s, GLP-1 drugs could lead to an annual revenue reduction of $30 billion to $55 billion for the global food and beverage industry.

Translation provided by third-party software.

Disclaimer: The market involves risks, and investment should be approached with caution. This article was generated by an AI large language model based on public information and does not represent the views of Sina Finance. All information, data, and charts contained herein are for reference only and do not constitute any form of investment advice or basis for decision-making. For accurate information, please refer to the actual announcements. If you have any questions, please contact: biz@staff.sina.com.cn.

Responsible Editor: Xiaolang Express